A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.

Mary Kate Anderson Meredith Johnson Lauren Thornburg Zachery Halford

Published in: The Annals of pharmacotherapy (2021)

Selumetinib exhibits impressive antitumor activity and sustained clinical benefit in patients lacking other viable treatment options. Further studies are warranted to determine the optimal age of initiation, treatment duration, and overall cost-effectiveness of selumetinib.

Keyphrases

end stage renal disease
ejection fraction
peritoneal dialysis
combination therapy
patient reported outcomes
patient reported
replacement therapy